Angiotensin II dependent cardiac remodeling in the eel Anguilla anguilla involves the NOS/NO system by Filice, M. et al.
lable at ScienceDirect
Nitric Oxide 65 (2017) 50e59Contents lists avaiNitric Oxide
journal homepage: www.elsevier .com/locate/ynioxAngiotensin II dependent cardiac remodeling in the eel Anguilla
anguilla involves the NOS/NO system
Mariacristina Filice a, 1, Daniela Amelio a, 1, Filippo Garofalo a, 1, Sabrina David b,
Alberto Fucarino b, c, Frank Bo Jensen d, Sandra Imbrogno, PhD a, *,
Maria Carmela Cerra, PhD a, **
a Department of Biology, Ecology and Earth Sciences (B.E.ST), University of Calabria, Arcavacata di Rende, CS, Italy
b Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Palermo, Italy
c Euro-Mediterranean Institute of Science and Technology, Palermo, Italy
d Department of Biology, University of Southern Denmark, Campusvej 55, DK-5230 Odense, Denmarka r t i c l e i n f o
Article history:
Received 12 October 2016
Received in revised form
8 February 2017
Accepted 13 February 2017
Available online 20 February 2017
Keywords:
AT2 receptor
ERK1-2
Hsp90
Myocardial growth
NOSTRINAbbreviations: ACE, Angiotensin Converting Enz
AngII, Angiotensin II; cGMP, cyclic Guanosine Mono
Endothelium; eNOS, endothelial Nitric Oxide Syn
Signal-Regulated Kinases1-2; Hsp-90, Heat shock p
NOS, Nitric Oxide Synthase; NOSTRIN, eNOS trafﬁck
buffered saline; PKG, protein kinase G; RAS, Renin-An
* Corresponding author. Lab. of Organ and System
Ecology and Earth Sciences, University of Calabria, 87
Italy.
** Corresponding author. Lab. of Organ and System
Ecology and Earth Sciences, University of Calabria, 87
Italy.
E-mail addresses: sandra.imbrogno@unical.it (S.
cerra@unical.it (M.C. Cerra).
1 These authors equally contributed to the work.
http://dx.doi.org/10.1016/j.niox.2017.02.007
1089-8603/© 2017 Elsevier Inc. All rights reserved.a b s t r a c t
Angiotensin II (AngII), the principal effector of the Renin-Angiotensin System (RAS), plays an important
role in controlling mammalian cardiac morpho-functional remodelling. In the eel Anguilla anguilla, one
month administration of AngII improves cardiac performance and inﬂuences the expression and local-
ization of molecules which regulate cell growth.
To deeper investigate the morpho-functional chronic inﬂuences of AngII on the eel heart and the
molecular mechanisms involved, freshwater eels (A. anguilla) were intraperitoneally injected for 2
months with AngII (1 nmol g BW1). Then the isolated hearts were subjected to morphological and
western blotting analyses, and nitrite measurements.
If compared to control animals, the ventricle of AngII-treated hearts showed an increase in compacta
thickness, vascularization, muscle mass and ﬁbrosis. Structural changes were paralleled by a higher
expression of AT2 receptor and a negative modulation of the ERK1-2 pathway, together with a decrease in
nitrite concentration, indicative of a reduced Nitric Oxide Synthase (NOS)-dependent NO production.
Moreover, immunolocalization revealed, particularly on the endocardial endothelium (EE) of AngII-
treated hearts, a signiﬁcant reduction of phosphorylated NOS detected by peNOS antibody accompa-
nied by an increased expression of the eNOS disabling protein NOSTRIN, and a decreased expression of
the positive regulators of NOS activity, pAkt and Hsp90. On the whole, results suggest that, in the eel,
AngII modulates cardiac morpho-functional plasticity by inﬂuencing the molecular mechanisms that
control NOS activity and the ERK1-2 pathway.
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Angiotensin II (AngII), the active end-product of the Renin-
Angiotensin System (RAS), is an octapeptide hormone that plays
important roles in the regulation of cardiovascular homeostasis and
ﬂuid osmolarity.
In mammals, AngII interacts with plasma membrane receptors
named AT1 and AT2 (for references see Ref. [1]) to modulate various
aspects of cardiac function, including chronotropism, inotropism,
and coronary vasomotility [2]. Moreover, by cross-talking with
growth-promoting and growth-inhibiting factors, as well as with
angiogenic molecules, AngII induces mammalian cardiac growth
and remodelling, particularly under pathologic conditions [3,4].
Within the complex humoral balance that controls mammalian
M. Filice et al. / Nitric Oxide 65 (2017) 50e59 51cardiac form and function, AngII interacts with the Nitric Oxide
Synthase (NOS)/Nitric Oxide (NO) system. By recruiting AT1 and/or
AT2-mediated transduction pathways, AngII decreases NO
bioavailability; in turn, by down-regulating the synthesis of
Angiotensin Converting Enzyme (ACE) and AT1 receptor, NO
counteracts AngII-mediated actions [5,6].
A functional RAS, homologus to that found inmammals, is present
also inﬁsh (seeRef. [7]). In teleost, AngIIwas identiﬁedandsequenced
in various species, including the chum salmonOncorhynchus keta [8],
the Japanese gooseﬁsh Lophius litulon [9] and the American eel
Anguilla rostrata [10]. Inparallel, several studies provided amolecular
and biochemical characterization of piscine AngII receptors (see for
example [11,12]). A cDNA sequence (GenBank accession number
AJ005132 [12]), with 60% homology with mammalian AT1, was re-
ported in the European eel A. anguilla [13]. A receptor sharing the
origin with mammalian AT2 has been observed in the Japanese eel
A. japonica [14]; lastly, an AT receptor able to bind mammalian anti-
AT2 antibody was detected in the cardiac tissues of A. anguilla [15].
The teleost heart is sensitive to both the short- and medium/
long-term modulation exerted by AngII (see for references
[2,13,15e17]). Among teleost, the eel represents an experimental
model till now largely used to decipher the complex modulatory
neuro-humoral networks involved in the ﬁsh heart modulation,
particularly in relation to the role of NO as a major organizer of
basal cardiac physiology and a key coordinator of physically and
chemically activated intracellular signalling (see Ref. [18] for ref-
erences). This is due to its great ﬂexibility in relation not only to the
basic cardiac design and elaborated neuroendocrine traits, but also
to its biochemical-metabolic plasticity and acclimatory potential-
ities (see Ref. [19] for references). Moreover, its relatively simple
cardiac design allows setting up in vitroworking heart preparation
which, mimicking the haemodynamic response of the in vivo heart,
generates physiological values of cardiac parameters [20].
By using an isolated and perfused working heart, it has been
demonstrated that in the eel A. anguilla AngII exerts a direct me-
chanical cardio-suppression mediated by a G protein-coupled AT1-
like receptor that, in turn, triggers a NO-cGMP-Protein Kinase G
(PKG) signal transduction pathway [2]. Moreover, if administered
for a month, AngII improves the performance of the eel heart,
enhancing its ability to sustain increased afterload [15]. These ef-
fects involve the AT2 receptor, and factors which regulate cell
growth [i.e. c-kit, heat shock protein 90 (Hsp-90), NO] and
apoptosis [i.e. apoptosis repressor with CARD domain (ARC)].
Based on these premises, the aim of this study was to analyze
morpho-functional inﬂuences exerted on the eel (A. anguilla) heart
by chronic (two months) exposure to AngII. In view of the crucial
role of NO in the mechanisms of cardiac rearrangement [21,22], the
interplay between AngII and the NOS/NO systemwas also analysed.
The results evidenced an inﬂuence of AngII on the structural
remodeling of the eel heart. This is suggested by an increase in the
compacta thickness, ventricle muscle mass, vascularisation, and in
the amount of collagen ﬁbres, both at perivascular and interstitial
level, observed in AngII-treated hearts. Structural modiﬁcations
were paralleled by a higher expression of the AT2 receptor, a
negative modulation of the phosphorylated extracellular signal-
regulated kinases1-2 (ERK1-2), and by changes in the expression
and localization of molecules which regulate NOS activity, such as
the protein kinase B (Akt), the eNOS disabling protein NOSTRIN,
and the heat shock protein 90 (Hsp90).
2. Materials & methods
2.1. Animals
Specimens of freshwater European eel (A. anguilla) weighing83,31 ± 5,39 g (mean ± SD; n ¼ 27), provided by a local hatchery,
were kept in aerated freshwater at room temperature (18e20 C)
for 8 weeks and fed twice a week with commercial ﬁsh food. Each
eel was anesthetized with tricaine methanesulfonate (MS222,
SIGMA-Aldrich Chemical Co., UK). Animal care and procedures
were in accordance with the U.S. National Institutes of Health's
Guide for the Care and Use of Laboratory Animals (NIH Publication
No. 85-23, revised 1996) and with Directive 2010/63/EU.
Two groups of animals have been used. Through intraperitoneal
injections on alternate days, each animal has been treated, for 8
weeks, with:
 Group 1 (n ¼ 13): 1 ml of physiological saline.
 Group 2 (n ¼ 14): 1 nmol AngII gBW1 in 1 ml of physiological
saline.
Animal treatment with saline or AngII and heart samples
collection were performed during 2013, i.e. before the new Italian
law about the care and use of Laboratory Animals, effective from
March 2014, in which the European eel is considered an endan-
gered species.
2.2. Chemicals
The homologue teleost octapeptide AngII [17] was purchased
from SIGMA. Solution was prepared in double-distilled water; di-
lutions were made in physiological saline immediately before use.
2.3. Experimental protocols
2.3.1. Morphological analysis
Hearts from control and AngII treated eels (n ¼ 3 for each
condition) were ﬁxed in MAW (methanol:acetone:water, 2:2:1) for
light microscopy and immunoﬂuorescence (for details see
Ref. [15]).
2.3.1.1. Collagen staining. Sections were stained with Sirius red for
collagen ﬁbers detection. Slides were observed under a light mi-
croscope (Zeiss Axioscope); images were digitalized by Axiocam
105 color (Zeiss).
2.3.1.2. Semithin sections. Hearts from control and treated eels
(n ¼ 3 for each condition) were ﬁxed in 2.5% glutaraldehyde. Small
cubes of tissue were taken from the middle anterior wall of the
hearts. The pieces were dehydrated, embedded in EPON 812 (Shell
Chemical Co., San Francisco, CA) and cutted (0.70 mm) with an ul-
tramicrotome (Ultra Cut, Leica). Sections were stained with meth-
ylene blue, and observed with LEICA optical microscope (LEICA
DM5000B). Images were digitalized by using Adobe Photoshop 7.0
and the morphometrical evaluations (compacta thickness, per-
centage of muscular and vascular compartment) were carried out
on images (10X magniﬁcation) using ImageJ 1.49v. Geometrical
scaling was performed prior to start measurements.
Compacta thickness was quantiﬁed by measuring the distance,
from the border, between the epicardium and endocardium. The
percentage of surface area occupied by empty spaces was calcu-
lated by thresholding on random images of different transverse and
longitudinal ventricular sections. The resulting area (in pixels) was
subtracted from the total area (in pixels) of the section, thus
obtaining the overall area of myocardium and vascular compo-
nents. Themyocardial surfacewas obtained by subtracting from the
overall area (myocardium plus vascular components) the vascu-
larized area (percentage of area occupied by vessels), quantiﬁed by
measuring each blood vessel (Adobe Photoshop CC15.2Portable).
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incubated with 1.5% BSA in TBS for 1 h. They were then incubated
overnight at 4 C with rabbit polyclonal antibodies directed against
NOSTRIN (cat# Sc-134803), AT2 receptor (cat# Sc-48452), and goat
polyclonal anti pNOS3-Ser1177 (cat# Sc-12972), diluted 1:100 in
TBS. All antibodies were from Santa Cruz Biotechnology, Inc., Hei-
delberg, German. For signal detection, after washing in TBS
(3  10 min), slides were incubated with FITC-conjugated anti
rabbit and anti-goat IgG (SIGMA, 1:100) and mounted with
mounting medium (Vectashield, Vector Laboratories Burlingame,
CA, USA). Slides were observed under a ﬂuorescence microscope
(Axioscope, Zeiss), and the images were digitalized by Axiocam 105
color (Zeiss). Negative controls were obtained on parallel sections
treated in the same manner, excluding primary antibody. For nu-
clear counterstaining, sections were incubated with Propidium
iodide (SIGMA; 1:10,000) for 5 min.2.3.2. Nitrite measurement
For nitrite measurements, hearts from control and AngII-treated
animals (n ¼ 4 for each condition) were washed in a phosphate-
buffered saline [50 mM phosphate buffer; pH 7.8; 85 mM NaCl;
2.4 mM KCl; 10 mM N-ethylmaleimide (NEM); 0.1 mM dieth-
ylenetriaminepentaacetic acid (DTPA)], and then dried on a paper
towel, weighed and frozen in liquid N2. Each heart was homoge-
nized in 50 mM phosphate buffer (4 mL mg1 tissue; pH 7.3), con-
taining 10 mM NEM (N-ethylmaleimide) and 0.1 mM DTPA
(diethyletriaminepentaacetic acid) to stabilize S-nitrosothiols.
Samples were centrifuged (2 min, 16,000 g, 4 C) and the super-
natant was immediately measured. Nitrite was measured by
reductive chemiluminescence, using a Sievers (Boulder, CO, USA)
NO Analyzer (NOA, model 280i) and previously described proced-
ures (see Ref. [23] for references).2.3.3. Western blotting and densitometric analysis
To evaluate whether chronic AngII treatment affects the
expression pattern of protein involved in cellular growth and NO
metabolism, western blotting analysis was performed on heart
extracts. Eel hearts of group 1 (control) and 2 (AngII treated) (n ¼ 3
for each condition) were rapidly immersed in liquid nitrogen and
stored at 80 C. The ventricle, separated from the atrium and the
bulbus arteriosus, was prepared according to Amelio et al. [24].
Amounts of 60 mg of proteins were separated on 8% SDS-PAGE gel
(for eNOS/peNOS detection) or 12% SDS-PAGE gels (for ERK1-2/
pERK1-2, NOSTRIN, Hsp90, Akt/pAkt, AT1 and AT2), and electro-
blotted on to a nitrocellulose membrane. For immunodetection,
blots were incubated overnight at 4 C with either rabbit polyclonal
antibodies directed against NOSTRIN, Akt1/2/3 (cat# Sc-8312),
pAkt1/2/3-Ser473 (cat# Sc-7985-R), ERK2 (cat# Sc-154), eNOS
(cat# N3893), or mouse monoclonal antibodies directed against
AT1 receptor (cat# Sc-57036), pERK1-2 (cat# Sc-7383), or goat
polyclonal antibody directed against pNOS3-Ser1177, Hsp90 (cat#
Sc-1055), AT2 receptor. eNOS was purchased from SIGMA; all other
antibodies were from Santa Cruz Biotecnology.
Peroxidase linked secondary antibodies (anti-rabbit and anti-
goat) (Amersham) were diluted 1:2000 in TBS-T containing 5%
non-fat dry milk. Immunodetection was performed by using an
enhanced chemiluminescence kit (ECL PLUS, Amersham). Autora-
diographs were obtained by exposure to X-ray ﬁlms (Hyperﬁlm
ECL, Amersham). Immunoblots were digitalized and the densito-
metric analysis of the bands was carried out using WCIF Image J
based on 256 grey values (0¼white; 256¼ black). Quantiﬁcation of
the bands was obtained by measuring (eight times on each band)
the mean optical density of a square area, after the background has
been subtracted.2.3.4. Statistics
Compacta thickness and vascularization rate were calculated on
5 images for each group; values represent the means ± SEM of 6
measurements for each image. Statistical signiﬁcance of differences
was assessed using the Student's t-test (*p < 0.05; **p < 0.005).
For densitometric analyses, values were expressed as
means ± SEM of absolute values from individual experiments;
statistic was assessed by unpaired t-test (**p < 0.005;
***p < 0.0005). GraphPad Prism software, version 4 (GraphPad
Software, San Diego, CA) was used for all the statistical analysis.
3. Results
3.1. Cardiac morphometry
Ventricular sections stained with Sirius red (Fig. 1A and B)
showed collagen ﬁbers localized both in the compacta and spon-
giosa. A higher amount of collagen ﬁbers, located around sub-
epicardial vessels, in coronary vessels wall, at the border between
compacta and spongiosa, and in the interstitium, has been detected
in the compacta with respect to the spongiosa. In the spongiosa,
collagen ﬁbers localized in the subendocardium and within inter-
stitial spaces. The hearts of AngII-treated animals show an increase
of collagen amount in all the above described structures (Fig. 1B).
Observations carried out on semithin sections (Fig. 1C and D)
show a signiﬁcant increase of ventricle muscularity in treated eels,
associated with an increased thickness of the compacta and
trabecular size in the spongiosa. AngII-treated animals also show an
increased compacta vascular compartment (Fig. 1E, G, F).
3.2. AngII receptors
To evaluate the inﬂuence of chronic AngII exposition on the
cardiac expression of AT1 and AT2 receptors, western blotting
analysis and immunoﬂuorescence were performed by using
mammalian anti-AT1 and AT2 antibodies.
AT1 receptor was undetectable by both immunoblotting and
immunoﬂuorescence. In contrast, densitometric analysis of the blot
with anti-AT2 antibody revealed an increased expression of this
receptor in AngII-treated hearts, with respect to the control
(Fig. 2D). Immunoﬂuorescence showed a different localization of
AT2 in the hearts of control and treated animals. In particular, AT2
signal was revealed in the myocardiocytes of control hearts
(Fig. 2A), and at the EE of AngII-treated hearts (Fig. 2B).
3.3. ERK1-2
As revealed by western blotting analysis performed on cardiac
extracts, prolonged exposition to AngII elicits a signiﬁcant decrease
of ERK1-2 phosphorylation in the hearts of AngII-treated animals
(Fig. 3A). This implicates a negative modulation of the ERK1-2
signaling in the chronic effects of AngII in the eel heart.
3.4. NOS/NO system
To evaluate the inﬂuence of AngII treatment on the cardiac NO
production, the concentration of nitrite was determined in heart
homogenates of both control and AngII-treated eels. Results
showed a signiﬁcant decrease of nitrite concentration in hearts
from treated animals compared with the control group (control:
1.33 ± 0.13 mmol L1; AngII-treated: 0.60 ± 0.04 mmol L1).
Western blotting of ventricular extracts revealed no signiﬁcant
differences in eNOS phosphorylation between control and treated
hearts (data not shown) accompanied by a slight decrease of pAkt
expression in treated animals (Fig. 3B). Moreover,
Fig. 1. Representative images showing morphological changes occurring in the eel ventricle after AngII treatment. (A, B) Sirius red staining of control (A) and AngII (B) treated
hearts. Collagen ﬁbers localize at subepicardial level (green arrows), in the vessels wall (blue arrows), at subendocardial level (black arrows) and in the interstitium (violet arrows).
(C, D) Methylene Blue stained ventricular cardiac semithin sections of control (C) and AngII (D) treated eels. After treatment, the increment of compacta thickness, and of muscular
and vascular (red arrows) components is evident. Inset C1 and D1 represent higher magniﬁcation of the vascularized area of control and AngII treated hearts, respectively. Statistical
signiﬁcances are reported in the corresponding histograms (E, F, G) (*p < 0.05; **p < 0.005). Values represent the means ± SEM of 6 measurements for each image (N ¼ 5). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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the heart of control and treated animals. In particular, while in the
control hearts, a peNOS signal was captured at the EE level and in
the cardiomyocytes of ventricle (Fig. 4A) and atrium (Fig. 4B), in
treated hearts the enzyme prevalently localized in the myo-
cardiocytes (Fig. 4D and E), only a weak signal appearing on the EE.
In addition, at vascular level, a reduction of the peNOS signal
(Fig. 4G) was observed in the vascular endothelium of treated an-
imals, with respect to the control (Fig. 4F).
In line with the reduction of pAkt expression, western blotting
analysis revealed a strong decrease in the expression levels of
Hsp90 after AngII treatment (Fig. 3C). This is accompanied by a
signiﬁcant increase in the expression of the eNOS disabling protein
NOSTRIN (Fig. 5D), a protein that negatively modulates eNOS ac-
tivity promoting the translocation of the enzyme from the plasma
membrane to intracellular vesicles ([25] and references therein).
Moreover, in both untreated (Fig. 5A) and AngII-treated (Fig. 5B)
hearts, immunoﬂuorescence localized NOSTRIN on the vascular
endothelium of the greatest vessels (Fig. 5C) and on the ventricular
EE, although at the endocardial level the signal appeared stronger
in AngII treated hearts (Fig. 5B).4. Discussion
In the present study we show, for the ﬁrst time, that chronic
(two months) treatment with AngII induces structural modiﬁca-
tions of eel ventricular wall and myocardial vessels. This remodel-
ling is paralleled by modiﬁcation of NO production, and by changes
in the expression and localization of molecules which regulate NOS
activity, such as the protein kinase B (Akt), the eNOS disabling
protein NOSTRIN, and the heat shock protein 90 (Hsp90).
With respect to the compact type of ventricular myoarchitecture
typical of homeotherm hearts, the mixed type ventricle of the eel
shows an outer layer of orderly and densely arranged bundles of
muscle tissue (named compacta), that enclose an inner spongiosa
made up of a crisscrossed array of myocardial bundles (trabeculae)
(see Ref. [26], for references). As revealed by morphological ana-
lyses, the cardiac ventricle of eels chronically exposed to AngII
undergoes structural modiﬁcations, becoming more “muscular-
ized” than untreated animals. This remodelling occurs at the level
of both compacta and spongiosa. In particular, when compared to
control animals, AngII-treated eels showed an increased compacta
thickness, and a larger diameter of the trabeculae that form the
spongiosa. These changes are accompanied by higher collagen
Fig. 2. (A, B) Representative images of AT2 immunolocalization in the ventricle of control (A) and AngII treated (B) eels. White arrow: myocardiocytes. Yellow arrows: endocardial
endothelium. Nuclei counterstaining: propidium iodide. Inset A1 and B1 represent a higher magniﬁcation of AT2 positive signal. (C) Negative control. (D) Western blotting and
densitometric analysis of AT2 in cardiac extracts of ctrl and AngII treated eels. In D, loaded protein amount was veriﬁed using anti-b-actin antibody. Statistical differences were
evaluated by unpaired t-test (***p < 0.0005). Data are the means ± SEM of 3 determinations for each group. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
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staining, particularly localized in the wall of subepicardial and
coronary vessels. Enhancement of the compact myocardium is a
strategy of cardiac growth that occurs in many ﬁsh species (Ciprinus
carpio: [27]; Salmo salar: [28]; Thunnus thynnus: [29]; Salmo
gairdneri: [30]). It was described in A. anguilla during ontogenetic
growth [26] and in response to one month exposure to AngII [15].
Of note, we observed in eels treated for twomonths with AngII that
the increment of the compact layer is accompanied by an increased
vascularisation. In non-mammalian vertebrates, the growing heart
increases capillarization of the compact myocardium through
tightly controlled local mechanisms, which include mechanical
(e.g. myocardial stretch), metabolic and growth factors such asvascular endothelial growth factor (VEGF) and basic ﬁbroblast
growth factor (bFGF) ([31] and references therein). Although the
speciﬁc mechanisms that control eel heart vascularisationwere not
analysed in our study, it is conceivable that the enlarged vascular
supply, which occurs in the compacta of the AngII-treated hearts,
may allow the heart to cope with the metabolic and energetic de-
mands of the deeper myocardial cells.
In mammals, AngII-dependent effects on myocyte growth
correlate with the activation of the AT1 receptor (see Ref. [32] for
references). Contrarily, the AT2 receptor, whose cardiac expression
is reduced after birth, is generally reported to either offset or
oppose the AT1-induced effects on cell growth, thusmediating anti-
growth and apoptotic actions [33]. However, Ichihara and co-
Fig. 3. Western blotting and densitometric analysis of pERK1-2/ERK1-2 (A), pAkt/Akt (B) and Hsp90 (C) in cardiac extracts of control and AngII-treated eels. In C, loaded protein
amount was veriﬁed using anti-b-actin antibody. Statistical differences were evaluated by unpaired t-test (**p < 0.005; ***p < 0.0005). Data are the means ± SEM of 3 de-
terminations for each group.
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dependent cardiomyocyte hypertrophy and cardiac ﬁbrosis. In
A. anguilla, the few available data correlate the growth-promoting
actions of AngII to the activation of a receptor able to bind
mammalian anti-AT2 antibody [15]. AT1 receptors were not detec-
ted in control and AngII-treated eels. Conversely, western blotting
and immunoﬂuorescence showed, in the heart of the two groups of
animals, a different expression and spatial localization of AT2 re-
ceptors. In fact, while in control hearts AT2 receptors are expressed
in few myocardiocytes, after AngII treatment, they localize more
widely in the EE. This suggests that, contrarily to mammals, in the
eel heart AT2 receptors participate to the mechanisms of remod-
elling induced by AngII. No data about a putative AngII-dependent
modulation of ATs expression are available in ﬁsh. Also in mammals
the molecular mechanisms responsible for the expression of the
AT2-R gene are not fully deﬁned, although an upregulation of the
AT2 expression has been observed in different experimental
models, also in response to AngII exposition, and in relation to
various physio-pathological conditions (references in Ref. [35]). It is
interesting to underline that, although eel AT2 shares its originwith
mammalian AT2 [14], it underwent a peculiar evolution after
divergence of its lineage [14]. This may explain the contrasting
features showed by this receptor in mammals vs teleost, as for
example the activation of second messengers [14], and thus the
different elicited responses.
Several studies in mammals reported that AngII exerts its ac-
tions on the heart by recruiting ERK1-2 (see for references [36]). This
kinase is known for its stimulatory role in the mechanisms of
myocardial proliferation and ﬁbrosis [37,38]. However, more recent
experiments performed on in vivo knock-out mice showed that
ERK1-2 signaling is not required for mediating cardiac hypertrophy
[39].
In mammalian cardiomyocytes, AngII, via AT1 and/or AT2-re-
ceptor stimulation, exerts distinct effects on ERK1-2 activity.
Through AT1 receptor it may induce ERK1-2 activation, while it may
inhibit ERK1-2-dependent pathway through AT2 receptor [40].
Consistent with these observations, we observed a signiﬁcant
reduction of the activated (phosphorylated) form of ERK1-2 in
AngII-treated animals. Since this is accompanied by an increased
expression of AT2 receptors, it is possible that ERK1-2 down-
regulation is mediated by the AngII-AT2 binding.
An important aspect of the molecular network guiding the
AngII-dependent cardiac morpho-functional modulation is the
cross-talk with the NO signaling. In mammals, in addition to the
AT2-mediated control of NO production (references in Ref. [41]),
AngII activates a number of signal-transduction pathways thatresult in reduced NO levels [42]. In turn, NO can counteract AngII-
dependent effects by down-regulating the synthesis of both ACE
and AT1 receptors [5,6]. Thus, NO generation is both downstream
and upstream the AngII-dependent cascade. At present, tissue
levels of nitrite, an oxidative NO metabolite, represents a marker of
constitutive NOS activity and consequently of NO generation [23].
Bymeasuring total nitrite concentration in endothelial cell cultures,
Li and co-workers observed an AngII-dependent reduction of
eNOS-dependent NO production [43]. In the present work, we
found a signiﬁcant decrease in the ventricle nitrite concentration
from 1.33 mmol L1 in control animals (which compares with other
ﬁsh species [44,45]) to 0.6 mmol L1 in AngII treated eels. This
suggests that chronic exposure to AngII is accompanied by a
reduced NO generation, possibly mediated by a blunted NOS
functionality. To analyse this possibility, we focused on the mo-
lecular modulation of NOS-dependent NO production, in particular
the protein-protein interactions that represent important post-
translational mechanism of eNOS. A variety of regulatory proteins
cooperate to ﬁnely control eNOS activity. This is the case of
calmodulin, Hsp90 and protein kinase B (Akt), that positively
modulate eNOS [46]. At the same time, negative eNOS modulators
include caveolin, and NOSTRIN [47,48]. The latter represents a
crucial eNOS trafﬁcking controller that, by binding the enzyme,
triggers its translocation from the plasmalemma to vesicle-like
subcellular structures, thus blunting eNOS-dependent NO produc-
tion [48,49].
In teleosts, as well as in agnathans and chondrichthyans, a ca-
nonical eNOS seems to be absent (see Ref. [50]). Nevertheless,
physio-pharmacological approaches, as well as NADPH-diaphorase
and immunolocalizationwith heterologousmammalian antibodies,
revealed the presence of an “eNOS-like” activity in the heart of
several teleost species [18,24,51e55]. Ongoing studies will clarify
this aspect. However, in the present study, by western blotting and
immunoﬂuorescence, we analysed whether and to which extent,
the reduced NO generation observed in the eel heart after chronic
exposure to AngII is associated with a modulation of eNOS con-
trolling proteins, Akt, Hsp90 and NOSTRIN. Compared to the con-
trol, AngII-treated hearts showed comparable expression of peNOS-
like enzyme, a slight decrease of p-Akt and a high decrement of
Hsp90. Akt-mediated activation of eNOS is strongly inﬂuenced by
the association between Hsp90 and the enzyme [56]. In fact, Hsp90
can either directly act as a scaffold factor between eNOS and Akt, or
indirectly prevent Akt dephosphorylation from protein phospha-
tase 2A [57]. In addition, decreased levels of Hsp90 are responsible
of a reduced displacement of caveolin-1 from eNOS [58], blunting
enzyme activity. The bio-molecular results obtained on the
Fig. 4. Representative images showing peNOS immunolocalization on cardiac sections of control (A, B, F) and AngII (D, E, G) treated eels. (A, D) ventricle, (B, E) atrium, (F,G) vessels.
Inset A1 and D1 represent a higher magniﬁcation of peNOS positive signal. (C) Negative control. White arrows: myocardiocytes. Yellow arrows: endocardial endothelium. Nuclei
counterstaining: propidium iodide. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 5. Representative images of NOSTRIN immunolocalization in ventricular sections of control (A) and AngII-treated (B, C) eels. NOSTRIN localized in endocardial (yellow arrows)
and vascular endothelium (red arrows). C: nuclear counterstaining with propidium iodide. (D) Western blotting of NOSTRIN in cardiac extracts of control and AngII treated eels.
Loaded protein amount was veriﬁed using anti-b-actin antibody. Statistical differences were evaluated by unpaired t-test (**p < 0.005). Data are the means ± SEM of 3 de-
terminations for each group. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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exposure to the hormone may induce a decrease of eNOS-like ac-
tivity by modulating the expression of its intracellular regulators
Akt and Hsp90. Of note, in AngII-treated hearts, we also found an
enhancement of ventricular NOSTRIN expression. To the best of our
knowledge, this is the ﬁrst evidence revealing the presence of this
protein in the teleost myocardium. In mammals, NOSTRIN binds
eNOS to induce its translocation and inactivation [48]. This binding
is selective for this NOS isoform. In the light of the debate about
NOSs characterization in teleost (see above), the presence of an
eNOS-selective binding partner in the eel heart supports the pos-
sibility that the piscine isoform is an eNOS-like enzyme. In parallel
with NOSTRIN detection, by immunoﬂuorescence we found on
ventricular sections of both untreated and treated eels that the
protein localizes on the vascular endothelium of greater vessels and
on the EE. In particular, in treated eels, the EE was characterized by
a higher NOSTRIN signal and a reduced peNOS localization. If, as in
mammals (see Ref. [59] for references), also in the eel heart a higher
NOSTRIN expression is responsible for a reduction of NO produc-
tion through enzyme inactivation requires further investigations.
Although in the present study wemainly focused on myocardial
and endocardial tissues, immunoﬂuorescence revealed that, also in
large vessels, chronic AngII treatment is accompanied by a reduc-
tion of peNOS signal that resemble those occurring on endocardial
cells. The functional signiﬁcance of these results in relation to the
AngII-mediated inﬂuence on cardiac remodeling in teleost was
unexplored in the present study. However, extensive evidence ex-
ists in mammals on the relationship between AngII and the NOS/NO system on both normal and pathological vascular homeostasis.
It was shown in mammals that AngII induces an increase in
endothelial oxidative stress, with subsequent adverse effects on
vascular function and a downregulation of eNOS activity (see
Ref. [60] for references). Thus, eNOSmodiﬁcations induced by AngII
affect the downstream NO activated signaling pathways with ef-
fects on the vascular tone. As shown in mammalian aortic rings,
AngII decreases endothelium-dependent relaxation, and this in
part contributes to endothelial dysfunction (references in [61]).
Based on these observations it is possible to speculate that in the eel
heart, chronic Ang-II treatment, by reducing vascular NO genera-
tion, may negatively affect vascular relaxation, and thus the
perfusion of the compact myocardium where larger vessels are
mainly located. Whether and to which extent the AngII-dependent
ventricular rearrangement as well as the related reduction of NO
production at both myocardial and vascular level may be beneﬁcial
or detrimental for the eel heart at the moment is unknown and
remains a topic for future research.
5. Conclusion
In conclusion, the present study provides large evidence that the
eel heart undergoes structural and molecular remodelling if
exposed for two months to the cardioactive hormone AngII. This
occurs through molecular mechanisms which involves modiﬁca-
tion of NO production, and changes in the expression and locali-
zation of molecules which regulate NOS activity. Although the
speciﬁc NOS isoform remains to be deﬁned, our results strongly
M. Filice et al. / Nitric Oxide 65 (2017) 50e5958suggest that in the eel the cardiac NOS/NO system acts as an
important coordinator/integrator of molecular signal cascades
which control cardiac form and function.
Future research will contribute to better decipher the complex
molecular neuro-humoral networks which control cardiac remod-
elling in ﬁsh. In this context, the use of animal models, such as the
eel, characterized by a remarkable morpho-functional adaptability
to a variety of environmental factors (temperature, partial pressure
of oxygen, pH, environmental pollutants, etc.) [19] could be of help.
In an evolutionary and comparative perspective, we hope that the
information on themolecular strategies of cardiac regulation in ﬁsh
will cross the boundaries of comparative, integrative and environ-
mental physiology, emerging also as a topic of interest and a source
of bioinspiration for human cardiovascular physiology.
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